

Ursula Kassner

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4567567/publications.pdf>

Version: 2024-02-01

31
papers

598
citations

516215

16
h-index

610482

24
g-index

34
all docs

34
docs citations

34
times ranked

937
citing authors

#	ARTICLE	IF	CITATIONS
1	Does Regular Lipid Apheresis in Patients With Isolated Elevated Lipoprotein(a) Levels Reduce the Incidence of Cardiovascular Events?. <i>Artificial Organs</i> , 2014, 38, 135-141.	1.0	70
2	Lipoprotein(a) – An independent causal risk factor for cardiovascular disease and current therapeutic options. <i>Atherosclerosis Supplements</i> , 2015, 18, 263-267.	1.2	54
3	Molecular characterization of familial hypercholesterolemia in German and Greek patients. <i>Human Mutation</i> , 2004, 23, 285-286.	1.1	39
4	Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia. <i>Atherosclerosis</i> , 2016, 253, 88-93.	0.4	35
5	Single Lipoprotein Apheresis Session Improves Cardiac Microvascular Function in Patients With Elevated Lipoprotein(a): Detection by Stress/Rest Perfusion Magnetic Resonance Imaging. <i>Therapeutic Apheresis and Dialysis</i> , 2009, 13, 129-137.	0.4	30
6	Therapeutic Potential of Mipomersen in the Management of Familial Hypercholesterolaemia. <i>Drugs</i> , 2012, 72, 1445-1455.	4.9	28
7	Gene Therapy in Lipoprotein Lipase Deficiency: Case Report on the First Patient Treated with Alipogene Tiparovec Under Daily Practice Conditions. <i>Human Gene Therapy</i> , 2018, 29, 520-527.	1.4	27
8	Lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients with familial hypercholesterolemia in Germany: The CaReHigh Registry. <i>Atherosclerosis</i> , 2018, 277, 314-322.	0.4	27
9	Hyperlipidemias in elderly patients: results from the Berlin Aging Study II (BASEII), a cross-sectional study. <i>Lipids in Health and Disease</i> , 2020, 19, 92.	1.2	22
10	Effect of Omega-3 Fatty Acid Supplementation on Oxylipins in a Routine Clinical Setting. <i>International Journal of Molecular Sciences</i> , 2018, 19, 180.	1.8	21
11	Treatment with PCSK9 inhibitors reduces atherogenic VLDL remnants in a real-world study. <i>Vascular Pharmacology</i> , 2019, 116, 8-15.	1.0	20
12	The size of apolipoprotein (a) is an independent determinant of the reduction in lipoprotein (a) induced by PCSK9 inhibitors. <i>Cardiovascular Research</i> , 2022, 118, 2103-2111.	1.8	20
13	Immunoabsorption of Agonistic Autoantibodies Against α_1 -Adrenergic Receptors in Patients With Mild to Moderate Dementia. <i>Therapeutic Apheresis and Dialysis</i> , 2016, 20, 523-529.	0.4	19
14	Quality of life in patients treated with lipoprotein apheresis. <i>Journal of Clinical Lipidology</i> , 2016, 10, 323-329.e6.	0.6	18
15	Evaluation of the role of STAP1 in Familial Hypercholesterolemia. <i>Scientific Reports</i> , 2019, 9, 11995.	1.6	17
16	The interrelations between PCSK9 metabolism and cholesterol synthesis and absorption. <i>Journal of Lipid Research</i> , 2019, 60, 161-167.	2.0	16
17	PCSK9 Inhibitors in a German Single-Center Clinical Practice: Real-World Treatment of Patients at High Cardiovascular Risk Over 68 Weeks. <i>American Journal of Cardiovascular Drugs</i> , 2021, 21, 83-92.	1.0	16
18	Mutation spectrum and polygenic score in German patients with familial hypercholesterolemia. <i>Clinical Genetics</i> , 2020, 98, 457-467.	1.0	13

#	ARTICLE	IF	CITATIONS
19	Performance characterization of a novel electronic number connection test to detect minimal hepatic encephalopathy in cirrhotic patients. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 456-463.	0.8	12
20	CaRe high â€“ Cascade screening and registry for high cholesterol in Germany. <i>Atherosclerosis Supplements</i> , 2017, 30, 72-76.	1.2	12
21	Autosomal Recessive Hypercholesterolemia in Three Sisters with Phenotypic Homozygous Familial Hypercholesterolemia: Diagnostic and Therapeutic Procedures. <i>Therapeutic Apheresis and Dialysis</i> , 2004, 8, 275-280.	0.4	11
22	Chylomicronemia From GPIHBP1 Autoantibodies Successfully Treated With Rituximab: A Case Report. <i>Annals of Internal Medicine</i> , 2020, 173, 764-765.	2.0	11
23	Clinical utility gene card for: Hyperlipoproteinemia, TYPE II. <i>European Journal of Human Genetics</i> , 2014, 22, 953-953.	1.4	10
24	Treatment with PCSK9 inhibitors induces a more anti-atherogenic HDL lipid profile in patients at high cardiovascular risk. <i>Vascular Pharmacology</i> , 2020, 135, 106804.	1.0	10
25	Severe hypertriglyceridemia in a patient heterozygous for a lipoprotein lipase gene allele with two novel missense variants. <i>European Journal of Human Genetics</i> , 2015, 23, 1259-1261.	1.4	9
26	An ellipsometry-based Alzheimer plaque mimic: Effect of Î²-amyloid, lipoprotein identity and apolipoprotein E isoform. <i>Journal of Colloid and Interface Science</i> , 2004, 276, 503-506.	5.0	7
27	Higher Lipoprotein (a) Levels Are Associated with Better Pulmonary Function in Community-Dwelling Older People â€“ Data from the Berlin Aging Study II. <i>PLoS ONE</i> , 2015, 10, e0139040.	1.1	7
28	Activation of Lipid Mediator Formation Due to Lipoprotein Apheresis. <i>Nutrients</i> , 2019, 11, 363.	1.7	7
29	Two novel LDL receptor mutations in familial hypercholesterolemia: C122Y and E296X. <i>Human Mutation</i> , 2001, 17, 354-354.	1.1	4
30	Clinical outcome of a patient with lysosomal acid lipase deficiency and first results after initiation of treatment with Sebelipase alfa: A case report. <i>Molecular Genetics and Metabolism Reports</i> , 2019, 20, 100479.	0.4	2
31	Dusty Punch Cards and an Eternal Enigma: High-Density Lipoproteins and Atherosclerosis. <i>Drugs</i> , 2014, 74, 513-520.	4.9	0